Author: Editor

Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with solid tumors.

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations.

Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read here: https://ascopubs.org/doi/full/10.1200/JOP.19.00581

Sai-Hong Ignatius Ou, MD PhD Health Science Clinical ProfessorChao Family Comprehensive Cancer Center University of California Irvine School of Medicine discusses these topics. NSCLC treatment options (circa February 2020 updated May 2020)Targeted therapy (FDA Approved indication)EGFR classical mutationsEGFR uncommon mutationsALK fusionROS1 fusionBRAF V600EMETex14+ NSCLC (Approved May 6, 2020)RET fusion (Approved May 8, 2020)Immunotherapy (FDA approved)Chemotherapy + IO for first-line treatment of Non-Sq NSCLC, Sq NSCLC, and SCLC. (PD-L1 expression agnostic)Single agent second line (PD-L1 expression agnostic)Chemotherapy (FDA approved)Chemo + anti-angiogenesis mAb (non-Sq NSCLC)Chemo + anti EGFR mAb (Sq NSCLC)Single agent + anti-angiogenesis mAb Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis…

David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations.

David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations.

Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3). Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.02745

Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3). Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.02745

Adilia Hormigo, MD of Mount Sinai Health System @MountSinaiNYC discusses the clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma.

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.

Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.

Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.

Udai Banerji, MD @udai_banerji of The Institute of Cancer Research and Jonathan Pachter, PhD of Verastem Oncology discuss the new opportunities and RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. Read here: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-preliminary-data-investigator

Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this May and expresses its support for all those affected by brain tumors. Brain tumors remain one of the greatest current health challenges as there are limited treatment options for patients, and prognoses continue to be poor. “In commemorating this month, we recognize not only the patients currently battling brain cancer, but also the families of those patients, the clinicians and caregivers treating them, the survivors, the patients who have lost their lives, and the researchers working to defeat this disease,” said…

Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read here: https://ascopubs.org/doi/full/10.1200/JOP.19.00581

Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. Read here: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-preliminary-data-investigator  

Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. Read here: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-preliminary-data-investigator

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations __________ The Breakthrough Therapy Designation is based on the overall response rate (ORR) and the long-term benefit seen in patients who responded in a Phase 1/2 study evaluating the safety and efficacy of mobocertinib in patients with locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations and have been previously treated with systemic chemotherapy. This signals a potential advancement in addressing the needs of patients for whom no targeted therapies exist…

Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual AACR 2020. Read here: https://www.clinicaltrials.gov/ct2/show/NCT03667716?term=NCT+03667716&draw=2&rank=1  

Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual AACR 2020. Read here: https://www.clinicaltrials.gov/ct2/show/NCT03667716?term=NCT+03667716&draw=2&rank=1  

Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual AACR 2020. Read here: https://www.clinicaltrials.gov/ct2/show/NCT03667716?term=NCT+03667716&draw=2&rank=1

Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the importance of real world outcomes among older women with breast cancer treated with neoadjuvant chemotherapy. Read here: https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2019-0891

Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes among older women with breast cancer treated with neoadjuvant chemotherapy. What advantages can this type of study give us? Read here: https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2019-0891

Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes among older women with breast cancer treated with neoadjuvant chemotherapy. Read here: https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2019-0891

Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer and patients as they progress on treatment. Read here; https://www.jci.org/articles/view/131041  

Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses if switch maintenance immunotherapy is a standard base treatment for urothelial cancer yet. ___________ The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients. “This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial cancer, a disease characterized by a…

Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. How do we identify a subgroup of patients? Read here: https://www.jci.org/articles/view/131041  

Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC answers what is the role of a switch maintenance immune checkpoint blockade approach? What does this mean for standard practice? _____________ The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients. “This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial…

Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed answers if the phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer can be expanded. Presented at this year’s AACR Annual Meeting.

Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Read here: https://www.jci.org/articles/view/131041  

Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. _________ The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients. “This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial cancer, a disease…

Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed discusses the phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer presented at this year’s AACR Annual Meeting.

Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. Read here: https://www.globenewswire.com/news-release/2020/04/09/2014287/0/en/Study-Shows-Guardant360-Test-Identifies-Predictors-of-Response-to-PIK3CA-Inhibitors-in-Women-with-HR-Metastatic-Breast-Cancer.html  

Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses the impact of multigenomic assays in premenopausal patients and those with node-positive breast cancer. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200006/full/?cid=DM4922&bid=42056373&

Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. Read here: https://www.globenewswire.com/news-release/2020/04/09/2014287/0/en/Study-Shows-Guardant360-Test-Identifies-Predictors-of-Response-to-PIK3CA-Inhibitors-in-Women-with-HR-Metastatic-Breast-Cancer.html

Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast cancer. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200006/full/?cid=DM4922&bid=42056373&

Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast cancer. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200006/full/?cid=DM4922&bid=42056373&

Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. Read here: https://www.globenewswire.com/news-release/2020/04/09/2014287/0/en/Study-Shows-Guardant360-Test-Identifies-Predictors-of-Response-to-PIK3CA-Inhibitors-in-Women-with-HR-Metastatic-Breast-Cancer.html

Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in late stage melanoma patients following vaccination with TriMix and tumor associated antigen mRNA modified dendritic cells plus ipilimumab. __________ For four cycles, monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix), as well as TAAs tyrosinase, gp100, MAGE-A3, and MAGE-C2 were administered along with ipilimumab. A supplementary vaccine was provided for 18/39 patients prior to the first administration of ipilimumab. In previously collected peripheral mononuclear blood cells, which were available for 15 of the…

Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants. __________ PARPs (poly-ADP-ribose polymerases) are a family of enzymes that regulate a wide variety of important cellular processes including cellular stress signaling pathways implicated in inflammation and cancer. PARP14 is a member of the monoPARP sub-family of PARPs, which catalyze transfer of a single ADP ribose unit (mono-ADP-ribosylation or MARylation) to their substrates, unlike their polyPARP counterparts which construct chains of ADP ribose units (poly-ADP-ribosylation or PARylation). PARP14 is an interferon-stimulated gene (ISG) that is overexpressed…

Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways: is this going to affect clinicians and treatment today? ________________ PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function (MARylation). PARP7 expression is increased by cellular stresses, including aromatic hydrocarbons and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I interferon (IFN) response by interacting with TBK1 during viral infection. As part of…

Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants. __________ PARPs (poly-ADP-ribose polymerases) are a family of enzymes that regulate a wide variety of important cellular processes including cellular stress signaling pathways implicated in inflammation and cancer. PARP14 is a member of the monoPARP sub-family of PARPs, which catalyze transfer of a single ADP ribose unit (mono-ADP-ribosylation or MARylation) to their substrates, unlike their polyPARP counterparts which construct chains of ADP ribose units (poly-ADP-ribosylation or PARylation). PARP14 is an interferon-stimulated gene (ISG) that is overexpressed…

Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in late stage melanoma patients following vaccination with TriMix and tumor associated antigen mRNA modified dendritic cells plus ipilimumab. __________ For four cycles, monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix), as well as TAAs tyrosinase, gp100, MAGE-A3, and MAGE-C2 were administered along with ipilimumab. A supplementary vaccine was provided for 18/39 patients prior to the first administration of ipilimumab. In previously collected peripheral mononuclear blood cells, which were available for 15 of the…

Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways. ________________ PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function (MARylation). PARP7 expression is increased by cellular stresses, including aromatic hydrocarbons and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I interferon (IFN) response by interacting with TBK1 during viral infection. As part of our drug discovery efforts to identify inhibitors of PARP7,…

Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in late stage melanoma patients following vaccination with TriMix and tumor associated antigen mRNA modified dendritic cells plus ipilimumab. __________ For four cycles, monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix), as well as TAAs tyrosinase, gp100, MAGE-A3, and MAGE-C2 were administered along with ipilimumab. A supplementary vaccine was provided for 18/39 patients prior to the first administration of ipilimumab. In previously collected peripheral mononuclear blood cells, which were available for 15 of the…

Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways. ________________ PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function (MARylation). PARP7 expression is increased by cellular stresses, including aromatic hydrocarbons and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I interferon (IFN) response by interacting with TBK1 during viral infection. As part of our drug discovery efforts to identify inhibitors of PARP7,…

Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine explains how important it is to tailor treatment for triple-negative breast cancer patients. _____________ Immunotherapies have revolutionized care for people with multiple cancers. But when offered to those with triple-negative breast cancer (TNBC), an particularly aggressive type of the disease, fewer than 20 percent respond. “A big question in the field has been, Why are the rest not responding?” says Rumela Chakrabarti, an assistant professor at Penn’s School of Veterinary Medicine. Chakrabarti and the colleagues illuminate the nature of the molecules at play. We identified a signaling mechanism that could be used for…

Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine answers how come interferon gamma is acting differently? _____________ Immunotherapies have revolutionized care for people with multiple cancers. But when offered to those with triple-negative breast cancer (TNBC), an particularly aggressive type of the disease, fewer than 20 percent respond. “A big question in the field has been, Why are the rest not responding?” says Rumela Chakrabarti, an assistant professor at Penn’s School of Veterinary Medicine. Chakrabarti and the colleagues illuminate the nature of the molecules at play. We identified a signaling mechanism that could be used for potential improved target therapies in…

Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine discusses tailoring revolutionary treatment for triple-negative breast cancer. _____________ Immunotherapies have revolutionized care for people with multiple cancers. But when offered to those with triple-negative breast cancer (TNBC), an particularly aggressive type of the disease, fewer than 20 percent respond. “A big question in the field has been, Why are the rest not responding?” says Rumela Chakrabarti, an assistant professor at Penn’s School of Veterinary Medicine. Chakrabarti and the colleagues illuminate the nature of the molecules at play. We identified a signaling mechanism that could be used for potential improved target therapies in…

Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews explains immunosuppression in tumors overall in the study. ______________ An active immune system plays an important role in stopping the development of cancer by detecting and targeting the tumor cells for destruction. Some change in the immune system’s normal activities can lead to accelerated growth of tumors. Researchers at the Moffitt Cancer Center decided to find out how myeloid cells, a form of immune cell, may contribute to cancer progression. The Moffitt team explains how protein-signaling pathways associated with cellular stress processes turn myeloid cells into tumor-promoting players, and indicates that targeting…

Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews answers what the effects are in activation for identifying molecular pathways that control immunosuppression in tumors. ______________ An active immune system plays an important role in stopping the development of cancer by detecting and targeting the tumor cells for destruction. Some change in the immune system’s normal activities can lead to accelerated growth of tumors. Researchers at the Moffitt Cancer Center decided to find out how myeloid cells, a form of immune cell, may contribute to cancer progression. The Moffitt team explains how protein-signaling pathways associated with cellular stress processes turn myeloid…

Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews discusses identifying molecular pathways that control immunosuppression in tumors. ______________ An active immune system plays an important role in stopping the development of cancer by detecting and targeting the tumor cells for destruction. Some change in the immune system’s normal activities can lead to accelerated growth of tumors. Researchers at the Moffitt Cancer Center decided to find out how myeloid cells, a form of immune cell, may contribute to cancer progression. The Moffitt team explains how protein-signaling pathways associated with cellular stress processes turn myeloid cells into tumor-promoting players, and indicates that…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create new helpful tools?…

In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create new helpful tools?…

In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create new helpful tools?…

In this video from our Cancer Basics series, Narjust Duma, MD, Assistant Professor and Thoracic Oncologist with the University of Wisconsin Carbone Cancer Center interviews Dr. Grace Blitzer, Radiation Oncology Resident with the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health. Dr. Blitzer shares with us a great description of what a CT Simulation Scan for Radiation Therapy is, how it is used, and why it is important for receiving radiation therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and how it affects the community. The second video in this 2 part series, presented in Spanish for the Latino community, covers information relating to the following topics: What is coronavirus? What are the common symptoms? How is it contracted, and how can it be prevented? Who is at risk, and are people with cancer at higher risk? Does the risk of exposure change my treatment for cancer? What happens if I get coronavirus and have cancer? I hear about treatments:…

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and how it affects the community. This 2 part series, presented in Spanish for the Latino community, covers information relating to the following topics: What is coronavirus? What are the common symptoms? How is it contracted, and how can it be prevented? Who is at risk, and are people with cancer at higher risk? Does the risk of exposure change my treatment for cancer? What happens if I get coronavirus and have cancer? I hear about treatments: are these now established…

In partnership with Clinical Care Options, GRACE President Jack West, MD provides information regarding immunotherapy for advanced NSCLC, and discussing goals and treatments with your health care providers.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Julia Maues, breast cancer patient and advocate, and founder of https://www.itsnot.pink/.In this interview, Dr. Duma interviews Julia about her journey as a cancer patient and becoming an advocate. This interview is done in Portuguese, for our global community. For more information (in english) about Julia’s journey, please visit https://www.itsnot.pink/my-story.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung cancer patient and advocate. In this series Juanita shares her inspiring story from diagnosis to today, showing how her positivity and optimism powers her through. In this third and final video Juanita shares with us her message – she is still living.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung cancer patient and advocate. In this series Juanita shares her inspiring story from diagnosis to today, showing how her positivity and optimism powers her through. In this second video Juanita discusses her treatment journey.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung cancer patient and advocate. In this series Juanita shares her inspiring story from diagnosis to today, showing how her positivity and optimism powers her through.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR Mutations. In an EGFR mutation with MET amplification, what are treatment decisions and what is the importance of the level of MET amplification?For more, please visit http://cancerGRACE.org/. To join…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations treated with Tagrisso, and with progression while on treatment, what is the role of repeat biopsy?For more, please visit http://cancerGRACE.org/. To join the conversation, visit…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect treatment decisions?For more, please visit http://cancerGRACE.org/. To…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR mutations, patient progression and next steps. Is there a place for chemo and the inclusion of immunotherapy? Where does immunotherapy fit in to the mix? For…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutation with high PDL-1 – does immunotherapy have a role in treatment? For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR mutations and what is the recommended treatment for common EGFR mutations.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations – is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions? For more, please visit http://cancerGRACE.org/. To join the…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations – is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions? For more, please visit http://cancerGRACE.org/. To join the…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to an EGFR mutation. In this video, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials.For more, please visit http://cancerGRACE.org/. To join the conversation, visit…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.The doctors discuss a series of cases related to a diagnosis of NSCLC. In this video, the discussion is regarding a patient with a HER2 mutation, what is the clinical significance, and how does a positive HER2 mutation effect treatment decisions?For more, please visit http://cancerGRACE.org/. To join…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive and high PDL-1. What is the first line treatment for potentially competing targets? For more, please visit…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/radiation and immunotherapy.For more, please visit http://cancerGRACE.org/. To join the conversation,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding progression after success on an ALK inhibitor. Do you continue the ALK inhibitor when transitioning to a chemo based treatment? For more,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss developing resistance to Alk inhibitors, treatment approaches and biopsies, and what are the next steps. For more, please visit http://cancerGRACE.org/. To join the conversation,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss developing resistance to Alk inhibitors, treatment approaches and biopsies, and what are the next steps. For more, please visit http://cancerGRACE.org/. To join the conversation,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal…

Terapias para el Cancer: Conocimientos Basicos (Cancer Therapy – Basics) ¿Que es oncologia geriátrica? What is Geriatric Oncology? Narjust (N.J.) Duma, MD, Assistant Professor And Thoracic Oncologist with the University of Wisconsin Carbone Cancer Center Provides us with more information for our Latino community. In this video Dr. Duma speaks with Enrique Soto Pérez de Celis, MD, a Medical Oncologist / Oncólogo Médico with the Department of Geriatrics / Oncología Geriátrica at the Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico. In this spanish language video Dr. Duma and Dr. Soto discuss geriatric oncology. For more,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J. Roboz and the symposium faculty discuss a series of cases that demonstrate the use of MRD testing in the treatment of hematologic malignancies. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Ajay Chari discusses the role of MRD in the treatment of multiple myeloma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Steven E. Coutre discusses the role of MRD testing in the treatment of chronic lymphocytic leukemia (CLL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J. Roboz discusses the role of minimal residual disease (MRD) testing in the treatment of acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Aaron C. Logan discusses the latest treatment guidelines for acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Prashant Kapoor provides an overview of the game-changing potential that MRD has in the treatment of hematologic malignancies. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab presents a case of advanced HCC that elucidates the role of immunotherapy. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Ghassan Abou-Alfa discusses novel agents and therapeutic targets for the treatment of biliary cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses best practices for the management of adverse events associated with the treatment of HCC. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Michael A. Choti argues in favor of utilizing adjuvant FOLFIRINOX for the treatment of pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-gdu… In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Jordan D. Berlin argues in favor of utilizing preoperative chemo/chemoradiotherapy for the treatment of pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Christopher L. Hallemeier argues in favor of utilizing stereotactic body radiation therapy (SBRT) for the preoperative treatment of borderline resectable pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Christopher Crane argues in favor of utilizing conventional radiation therapy for the preoperative treatment of borderline resectable pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab presents a case of hepatocellular carcinoma (HCC) that elucidates the role of imunotherapy. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses the best practices for the management of adverse events associated with therapies utilized in the treatment of hepatocellular carcinoma (HCC). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse Events Management’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, the session panel discuss cases elucidating the finer points of individualized treatment selection and therapeutic sequencing in next-line metastatic colorectal cancer. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-7 This webcast features a presentation by Dr. Gary H. Lyman that examines the potential benefits of incorporating biosimilars into oncology clinical pathways. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-6 This webcast features a presentation by Dr. Alexander B. Olawaiye that discusses the integration of PARP inhibitors into evidence-based ovarian cancer clinical pathways based on discrete PARP factors, latest clinical data, and guideline recommendations for the treatment of ovarian cancer. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-5 This webcast features a presentation by Dr. Atish D. Choudhury that examines the latest clinical safety and efficacy data surrounding next-generation antiandrogen agents for initial treatment of localized hormone-sensitive prostate cancer (HSPC). © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-4 This webcast features a presentation by Dr. Amir T. Fathi on best practices for the integration of recent therapeutic advances, resource utilization data, and current guidance into AML clinical pathways discussions. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-3 This webcast features a presentation by Dr. David Jackman discusses the latest efficacy and safety data, indications, and cost utility of novel therapies into optimal selection and non-small cell lung cancer (NSCLC) pathway placement strategies. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-2 This webcast features a presentation by Dr. Gabriella Hobbs that examines the most recent evidence-based guidelines to optimize individualized tyrosine kinase inhibitor (TKI) selection for chronic myeloid leukemia (CML) patients based on disease phase, treatment history, genetic mutation profile, and comorbidities, © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-1 This webcast features a presentation by Dr. Nicole M. Kuderer that examines pharmacological profiles of novel and emerging metastatic breast cancer (MBC) agents, including their indications, potential place in therapy, and recent clinical data. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-15 In this webcast from the ‘New and Emerging Agents in MCL’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Michael E. Williams discusses novel agents for the treatment of mantle cell lymphoma (MCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-14 In this webcast from the ‘Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. John P. Leonard discusses the current state of upfront management of diffuse large b-cell lymphoma (DLBCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Thomas M. Habermann discusses the treatment of marginal zone lymphoma (MZL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Thomas M. Habermann discusses whether treatment of marginal zone lymphoma (MZL) should be different than that of follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Martin, Casulo, Fischer, Cheson, and Haberman discuss the treatment of lymphoma on a panel discussion. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Bruce D. Cheson and Richard I. Fisher debate whether chemotherapy still has a major role in the treatment of follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Peter Martin and Carla Casulo debate whether patients with follicular lymphoma should be treated immediately. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Barrientos and Park discuss their presentations and answer questions on the treatment of hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Jae Park discusses new and emerging treatment options for patients with hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Jacqueline C. Barrientos discusses the efficacy and safety of current treatment options for hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Steven B. Treon discusses treatment options for a a series of cases of Waldenström’s Macroglobulinemia. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Steven B. Treon discusses his approach to the treatment of Waldenström’s Macroglobulinemia. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. James R. Berenson, Adam D. Cohen, Deepu Madduri, and Sham Mailankody discuss the current and future state of CAR-T therapy for myeloma patients. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Adam D. Cohen discusses next-generation CAR-T produces and strategies. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Sham Mailankody discusses responses to CAR-T therapy in patients with myeloma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. James R. Berenson discusses the role of b-cell maturation antigen (BCMA) in predicting outcomes and monitoring patients with multiple myeloma or chronic lymphocytic leukemia. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Raphael Fonseca discusses use the of MRD testing, single cell RNA sequencing, and cell free DNA testing in the treatment of hematologic malignancies. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses the use of MRD as a target for the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Desai, Lee, Roboz, and van Besien discuss their presentations and answer questions. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Pinkal Desai and Sangmin Lee debate whether patients in major molecular remission © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Sangmin Lee discusses current approaches to optimizing care. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Desai, Lee, and Roboz elaborate on their presentations from the symposium. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Pinkal Desai and Sangmin Lee debate whether venetoclax + azacitidine/decitabine/LDAC should be the new standard of care for acute myeloid leukemia (AML) patients greater than equal to 60 years of age. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses novel targeted therapies for the treatment of newly diagnosed acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses novel therapies for the treatment of newly diagnosed acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-04 In this webcast from the ‘Recent Advances in Acute Leukemia Management’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Pinkal Desai discusses therapeutic strategies for the difficult-to-treat patient with acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the ‘Multiple Myeloma: Treatment Challenges and Updates’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Deepu Madduri discusses best practices for dealing with adverse events and toxicities related to CAR-T therapy.

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the alkylating properties in the treatment of relapsed/refractory multple myeloma. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update on the final study…

Zachary Frosch, MD of Penn Medicine @PennMedicine explains that more prospective data is needed to validate stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe…

Zachary Frosch, MD of Penn Medicine @PennMedicine answers how stratification of molecular risk in aggressive b-cell lymphoma is validated. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe lymphoma, the findings of which…

Zachary Frosch, MD of Penn Medicine @PennMedicine discusses stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe lymphoma, the findings of which have often led…

According to GlobalData, a leading data and analytics firm, India-based Curadev’s March 2020 licensing agreement with Bayer for the discovery and production of novel interferon gene stimulators (STING) antagonists across indications with high unmet need indicates the importance of the STING mechanism for research by top pharmaceutical companies. As part of the partnership, Bayer acquires exclusive access to the software of novel STING antagonists. The firms will jointly develop new drugs for lung cancer, cardiovascular disease and other inflammatory diseases. In 2019 Curadev approved Takeda’s STING agonist software (CRD5500). Under the deal, in addition to research funding, Curadev will receive…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the next steps for the ongoing trial once they receive FDA approval and provides insight into the lighthouse clinical trial. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides answers where does melphalan flufenamide fit in the mix of RRMM treatment if broad-spectrum agents dominate? ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an…

OneOncology, the national association of independent group oncologists, said today that enrolling patients at their affiliate practices in clinical trials has increased marginally in March and April, just as the COVID-19 pandemic struck our communities hardest.  Clinical trial accruals occurred at a steady to slightly higher pace at OneOncology partner practices in March and April, while news outlets reported hundreds of clinical trials across the country have been suspended since March 1 due to the outbreak, especially in hospital-based settings that are disproportionately affected by the pandemics. “Elective medical procedures have stopped, but caring for cancer patients isn’t elective,” said…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses results of the HORIZON phase 2 data in RRMM. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update on the final study results…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the combination of the pivotal phase 2 study, HORIZON and phase 3 study, OCEAN, becoming key studies for melphalan flufenamide in the US and the EU. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the significance of the latest data findings from the O-12-M1 clinical trial recently published. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the 5 clinical trials for the treatment of relapsed/refractory multiple myeloma: O-12-M1, Horizon, Ocean, Anchor and Bridge. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to…

Ron Peck, MD, CMO of Arvinas @Arvinas on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost all of a…

Ron Peck, MD, CMO of Arvinas @Arvinas answers common questions on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost…

Ron Peck, MD, CMO of Arvinas @Arvinas discusses the initial safety and PK data on an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein…

Ron Peck, MD, CMO of Arvinas @Arvinas discusses an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. Dr. Peck further explains the approach to targeted protein degradation and why it might have potential in oncology. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as…

Dr. Mark Tuthill, MD of University of Oxford explains the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy and the key steps to phase 3. _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech programs…

Dr. Mark Tuthill, MD of University of Oxford answers the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy: are they accepting new patients for the study? _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech…

Dr. Mark Tuthill, MD of University of Oxford discusses the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy. _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech programs of the European Commission. The research aims…

Dr. James Bates, MD @JamesBatesMD of University of Florida @UF answers is this reflective of long term techniques on long term outcomes in 10-year survivors of early-stage hodgkin lymphoma. ___________ Although radiation therapy enhances progression-free survival in early-stage Hodgkin lymphoma (HL), significant questions remain about the effect on quality of life and survival of delayed normal tissue impacts. We hypothesized that combined-modality therapy (CMT; chemotherapy and radiation therapy) care increases overall survival among 10-year survivors as opposed to radiation therapy or chemotherapy care alone.

Dr. James Bates, MD @JamesBatesMD of University of Florida @UF discusses long term outcomes in 10-year survivors of early-stage hodgkin lymphoma. ________ Although radiation therapy enhances progression-free survival in early-stage Hodgkin lymphoma (HL), significant questions remain about the effect on quality of life and survival of delayed normal tissue impacts. We hypothesized that combined-modality therapy (CMT; chemotherapy and radiation therapy) care increases overall survival among 10-year survivors as opposed to radiation therapy or chemotherapy care alone.

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or crizotinib, 250 mg twice daily. In the ALUNBRIG arm the…

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. What is Intracranial Efficacy in ALUNBRIG for ALK + NSCLC? ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or…

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or crizotinib, 250 mg twice daily. In the ALUNBRIG arm the…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL): how this affects clinicians and what is to come.   venetoclax-rituximab, VenR, chronic lymphocytic leukemia, CLL, murano study

Philadelphia, PA (April 7, 2020) – Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel class of compounds called imipridones, announced today that Wolfgang Oster, MD, PhD, one the company’s co-founders and Chief Executive Officer, has left the company effective April 3 as part of a leadership change.  He has also left the company’s Board of Directors. Raymond Wong, a director associated with the company’s lead investor, Spring Mountain Capital, is now the company’s Chairman. Lee Schalop, MD, the company’s Chief Operating Officer, is now Chief Executive Officer. Martin Stogniew, PhD, remains the company’s Chief Development Officer. Josh…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews explains the phase II trial in effective immunotherapy with markers of immune activation in metastatic prostate cancer.  While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, M.D., Ph.D.,…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews answers if the markers are predictive of outcomes on immunotherapy with markers of immune activation in metastatic prostate cancer. While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi,…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer. While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, M.D., Ph.D., assistant professor of Genitourinary Medical Oncology.…

David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai: how information is generated. A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a…

David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai. A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a patient benefiting from FOLFOX…

A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a patient benefiting from FOLFOX in combination with bevacizumab as a first-line regimen. Two separate data sets…

Dr. Giuseppe Curigliano, MD, PhD @curijoey of University of Milan on patient care and COVID-19 containment in Italy. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200068/full/?cid=DM4782&bid=40579286

Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth discusses the patients with newly diagnosed glioblastoma, initial experience with scalp saving radiation using combined temozolomide and tumor treatment fields (SPARE). Glioblastoma care quality involves concomitant chemoradiation and temozolomide management with tumor treatment fields (TTF fields). Preclinical studies indicate synergistic effects of TTF fields, and radiation therapy. We record our initial experience evaluating scalp-sparing radiation toxicity and tolerability with concurrent TTFields. This is a pilot test with one arm (Clinicaltrials.gov Identifier: NCT03477110). Adult patients (age from 18 years) with KPS from 60 years of age were eligible for newly diagnosed glioblastoma. All…

Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses important points to note on the rapidly changing COVID-19 for cancer patients and treatment. Early reports concerning cancer patients from Wuhan, China — the initial COVID-19 pandemic epicenter — indicate that many have contracted the coronavirus while in hospital care. That may mean that this vulnerable group may need to consider delaying treatment for cancer to help reduce their chances of infection.  Read here: https://www.webmd.com/lung/news/20200325/covid-19-may-delay-some-cancer-treatments#1

Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses COVID-19 possibly delaying cancer treatments because during treatment, patients may be exposed to the coronavirus. Early reports concerning cancer patients from Wuhan, China — the initial COVID-19 pandemic epicenter — indicate that many have contracted the coronavirus while in hospital care. That may mean that this vulnerable group may need to consider delaying treatment for cancer to help reduce their chances of infection.  Read here: https://www.webmd.com/lung/news/20200325/covid-19-may-delay-some-cancer-treatments#1

Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth answers common questions asked on the patients with newly diagnosed glioblastoma, initial experience with scalp saving radiation using combined temozolomide and tumor treatment fields (SPARE).  Glioblastoma care quality involves concomitant chemoradiation and temozolomide management with tumor treatment fields (TTF fields). Preclinical studies indicate synergistic effects of TTF fields, and radiation therapy. We record our initial experience evaluating scalp-sparing radiation toxicity and tolerability with concurrent TTFields. This is a pilot test with one arm (Clinicaltrials.gov Identifier: NCT03477110). Adult patients (age from 18 years) with KPS from 60 years of age were eligible for…

What is KEYNOTE-189? Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses important points to note in NSCLC. In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up to 35 cycles in total. In the placebo-combination category, eligible patients…

Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer answers common questions on KEYNOTE-189. If the PD-L1 expression is less than 1%, should therapy for pembrolizumab be considered in NSCLC? In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up…

Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co., Ltd., of the initiation of a Phase I/II clinical study of OP-10 (the Japanese name for ONC201) in Japan and the administration of the drug to the first patient.  ONC201 is a novel small molecule with a unique mechanism of action that has demonstrated anti-cancer activity and safety in preclinical models and in several ongoing clinical trials, including clinical trials in adult and pediatric patients with high-grade glioma. In February 2019, Oncoceutics outlicensed rights to ONC201 for Japan to Ohara. Under…

Philadelphia, PA (March 26, 2020) – Oncoceutics, Inc. announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a Composition of Matter patent for ONC201, the company’s lead development candidate, as well as for several other compounds of the imipridone family.  This new patent, along with a Composition of Matter patent for ONC201 issued in the United States in March 2019 and an intention to grant from the European Patent Office issued in August 2019, gives Oncoceutics extensive coverage for ONC201 around the world.  Oncoceutics licensed this group of patents from The Scripps Research Institute…

Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses an updated analysis on KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for untreated metastatic NSCLC. In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up to 35 cycles in…

Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation explains that COVID-19 infection rate is doubled for cancer patients. The coronavirus disease, called COVID-19, is in the minds of many people at the front and centre. For so many this is troubling, particularly for cancer patients and their families. Now declared by the World Health Organization (WHO) as a pandemic, the majority of people who develop COVID-19 experience only mild symptoms, including colds. WHO says that 80 percent of COVID-19 people are recovering without needing any specialist care. According to the CDC, some groups, including elderly adults and…

Heinz-Josef Lenz, MD Professor of Medicine and Preventive Medicine Associate Director, Clinical Sciences J Terrence Lanni Chair in Cancer Research Director, USC Center for Molecular Pathways and Drug Discovery USC / Norris Comprehensive Cancer Center outlines an Update on Molecular Targeted Therapies for Metastatic colorectal cancers including in depth conversation on Next-generation sequencing, The Colorectal Cancer Subtyping Consortium, bevacizumab, EGFR, 80405 trial, Gerlinger et al., NEJM 2012, Circos plot illustrating genome-wide CNA, Liquid Biopsies, KRAS, MGH GI, RAS-WT CRC, ctDNA, CALGB, SWOG 80405, Cetuximab, FOLFIRI, FOLFOXIRI, CRICKET Trial, PD-1 Blockade, Nivolumab Monotherapy, BRAF, HER2 Overexpression,Trastuzumab,HER2, ZW25, DS-8201a, BEACON CRC Phase…

Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation discusses the intersection of COVID-19 and lung cancer patients. The coronavirus disease, called COVID-19, is in the minds of many people at the front and centre. For so many this is troubling, particularly for cancer patients and their families. Now declared by the World Health Organization (WHO) as a pandemic, the majority of people who develop COVID-19 experience only mild symptoms, including colds. WHO says that 80 percent of COVID-19 people are recovering without needing any specialist care. According to the CDC, some groups, including elderly adults and people…

Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and Controversies, STAMPEDE: (Docetaxel) in mHSPC, LATITUDE Trial, docetaxel, ENZAMET, SWOG S1802, TITAN, mCRPC, Cabazitaxel, Enzalutamide, Radium223, Sipuleucel-T, Docetaxel (TAX), ADT, A031201, EORTC 1333 / PEACE III2, PARP inhibitors, TOPARP- B, niraparib, rucaparib, talazoparib, PHASE III PROFOUND, Pembrolizumab, KEYNOTE-991, 177-Lu PSMA, VISION trial, CAR-T, BiTE antibody, Erdafitinib, FGFR TKI, Enfortumab, EV 302, Docetaxel, Vofatamab, nivoluamb and more at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology …

Zev A. Wainberg, MD Associate Professor Of Medicine Co-Director GI Oncology Program David Geffen School of Medicine at UCLA gives an update in Gastrointestinal Cancers including KEYNOTE-059, Pembrolizumab, MSI-H KN 059, MSI-H KN 059 061, KEYNOTE 181, KEYNOTE-062, KEYNOTE 59, KEYNOTE-811, CHECKMATE-649, Javelin Gastric 100, SPOTLIGHT (FAST-2) 1L Claudin+, FIGHT 1L FGFR2, PRODIGE 24/CCTG PA.6 trial at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in Breast CancerSummary of 2019 practice changing studies Overall Survival UpdatesCDK 4/6 Inhibitors: MONALEESA 3, 7 and MONARCH 2, Adjuvant Pertuzumab: APHINITY, ER+, First PI3K Inhibitor Approval: SOLAR-1, HER2+, Tyrosine Kinase Inhibitors: NALA, HER2CLIMB, New ADC: DESTINY-Breast01Triple Negative, Checkpoint Inhibitor in mBC: IMpassion130 Neoadjuvant Checkpoint Inhibitors: KEYNOTE-522, NeoTRIP at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Herbert Eradat, MD, MS @dgsomucla Associate Clinical Professor UCLE Lymphoma Program UCLA BMT & CAR-T Cell Program, David Geffen School of Medicine UCLA discusses An Update on Diffuse Large B-Cell Lymphoma Novel Therapeutic Strategies at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Nagi El Saghir, MD @NagiSaghir of American University of Beirut Medical Center @AUBMC_Official discusses how to care for oncology patients and being educated during the current COVID-19 pandemic. As with the majority of the world’s population, hematologists, oncologists and their patients are now on the alert to face the COVID-19 pandemic worldwide. Indeed we are among the most worried as our patients might be more vulnerable. Owing to regular routine visits to clinics and hospitals, our patients are at higher risk of contracting the virus and, if they acquire COVID-19, they are at higher risk of severe complications and mortality…

Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA answers common questions on the characteristics and trends in adult acute lymphoblastic leukemia. There is still a survival benefit for patients who are referred, even if they do not undergo transplant, because of therapy and clinical trials. ______________ It is difficult to treat acute lymphoblastic leukemia (ALL) in a socioeconomic distressed community without ready access to a center for hematopoietic stem cell transplantation (HCT), and clinical trials. Sparse data concerning the outcomes of these patients. This retrospective study included 90 consecutive ALL patients, who presented between 2003 and 2018 to Harbor-UCLA.…

Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA discusses the characteristics and trends in adult acute lymphoblastic leukemia. The primary objective was overall survival. Secondary objectives included leukemia-free survival, toxicities of therapy, and referral for HCT and incidence of successful HCT. ALL in a vulnerable population without access to an HCT center is challenging. ______________ It is difficult to treat acute lymphoblastic leukemia (ALL) in a socioeconomic distressed community without ready access to a center for hematopoietic stem cell transplantation (HCT), and clinical trials. Sparse data concerning the outcomes of these patients. This retrospective study included 90 consecutive ALL…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer explains CAR-T treatment in hematological malignancies affecting clinicians and moving forward with the COVID-19 pandemic. Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer answers commong questions on CAR-T treatment in hematological malignancies and the toxicities used. Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that underlie disease…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer discusses CAR-T treatment in hematological malignancies.   Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that underlie disease relapse, adverse effects and cost. This…

This quick tutorial shows in detail how to create an account on OncologyTube.com and how to upload a video. The account is free and you will be able to add oncology and cancer specific videos and share them with our robust health care professional network.

Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director, Experimental Therapeutics Cedars Sinai Foundation discusses the Multi-Modality Management of Melanoma in the Era of Immunotherapy This presentation is a part of the MOASC Oncology Summit Annual Educational Symposium This presentation was made possible by these companies: Abbvie Oncology Amag Pharmaceuticals AstraZeneca Bayer Oncology BeiGene Clovis Oncology Coherus BioSciences Daiichi-Sankyo Jazz Pharmaceuticals Merck Pfizer Oncology Puma Biotechnology Takeda Oncology Tempus Verastem Oncology Walgreens    

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia: how this affects clinicians and treatment. _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly…

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia: what is the significance of this? _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly…

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia. _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly doses of rituximab 375 mg /…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews addresses how the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer affects clinicians and treatment today. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and PFS were the…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews answers if this can be extended to the community on the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and…

Company completes CLIA Validation of DetermaIOâ„¢, previously the Insight Genetics IM Score Test, establishing the test as a reliable and robust assay for identifying patients likely to respond tocheckpoint inhibitor therapy Data presented at the SITC conference in 2019 suggested that DetermaIOâ„¢ outperforms PD-L1 testingand Tumor Mutational Burden (TMB) in predicting both responders and non-responders to checkpointinhibitors Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it had completed CLIA Validation for DetermaIOâ„¢, previously the Insight Genetics IM Score Test. The company…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews discusses the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and PFS were the prespecified coprimary endpoints. TTB, a composite…

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses the effects of cardiac toxicities in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. ____________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer answers common questions in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. Does this data reflect our everyday practice? ____________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. ______________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Experience with COVID-19 in Wuhan, China shows up to half of patients present with a digestive symptom as chief complaint Digestive symptoms are common in COVID-19, occurring as the chief complaint in nearly half of patients presenting to hospital according to a new descriptive, cross-sectional multicenter study from China by investigators from the Wuhan Medical Treatment Expert Group for COVID-19 published today in The American Journal of Gastroenterology, the official publication of the American College of Gastroenterology. Most patients with COVID-19 present with typical respiratory symptoms and signs. However, early experience with the outbreak in Wuhan, China revealed that many patients…

Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via free online article in JNCCN—Journal of the National Comprehensive Cancer Network Experts from the Seattle Cancer Care Alliance (SCCA)—a Member Institution of the National Comprehensive Cancer Network® (NCCN®)—are sharing insights and advice on how to continue providing optimal cancer care during the novel coronavirus (COVID-19) pandemic. SCCA includes the Fred Hutchinson Cancer Research Center and the University of Washington, which are located in the epicenter of the COVID-19 outbreak in the United States. The peer-reviewed article sharing best practices is available for free online-ahead-of-print via open access…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers if this will affect clinicians and treatment for progression-free survival for breast and kidney cancer may extend survival for head and neck cancer patients. ______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers what type of TP53 mutations benefited from this for a drug used for breast and kidney cancer may extend survival for head and neck cancer patients. _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers questions on immunotherapy for a drug used for breast and kidney cancer may extend survival for head and neck cancer patients. _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and the advantage continued…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO discusses a drug used for breast and kidney cancer may extend survival for head and neck cancer patients.  _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and the advantage continued for those with mutations…

 VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL)   – Approval is based on data from the Phase 3 CLL14 trial, which showed that patients treated with obinutuzumab plus one year of treatment with VENCLYXTO had superior progression-free survival (PFS) and higher rates of undetectable minimal residual disease compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil[1],[5]   NORTH CHICAGO, Ill., March 12, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC)…

Allison King, MD of Washington University School of Medicine @WUSTLmed answers the gender disparities in hematology research: how this will affect clinicians and treatment. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification…

Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the results on gender disparities in hematology research success. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification as a carer was…

Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the study on gender disparities in hematology research success. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification as a carer…

Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results: a possible impact on broader therapy. Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results: what is the mechanism and how does it work?  Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Tom Davis, MD @ThomasADavisMD of @GenoceaBio discusses the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results in Q2/Q3 2020. Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19 and new projects that are either oncologically oriented or immune regulatory. #cancer #covid19 #coronavirus #immune #cancer #biotherapies #treatment #covid19 #coronavirus _____________ Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year partnership to create new, fully human antibodies to treat and prevent various diseases including oncology and immunology. The collaboration will also use the H2L2 Harbor Mice ® platform to produce monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies may be…

Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19. #cancer #biotherapies #treatment #covid19 #coronavirus __________ Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year partnership to create new, fully human antibodies to treat and prevent various diseases including oncology and immunology. The collaboration will also use the H2L2 Harbor Mice ® platform to produce monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies may be used therapeutically for people exposed to the virus, or prophylactically for people at high risk…

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC affecting clinicians and treatment. #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC: how did the patients do? #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

JNJ-6372, a dual-targeting EGFR-MET bispecific antibody, is being investigated for adults with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion mutations The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[i] Currently, there are…

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC.  #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells: how does this affect clinicians today? _____________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The Mount Sinai team reports that modulation of metabolic…

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells, potentially opening a new approach for bone marrow transplant: what about human stem cells? _______________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The…

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell discusses a way to enhance the potency of blood-forming stem cells, potentially opening a new approach for bone marrow transplant. _______________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The Mount Sinai team reports that…

Mount Sinai researchers have discovered a way to enhance the potency of blood-forming stem cells, potentially opening the door to a new approach for bone marrow transplantation, according to a study being published on February 27 in Cell Stem Cell. The scarcity of blood-forming stem cells, known as hematopoietic stem cells (HSCs), severely limits bone marrow transplantation, which can cure many blood disorders and solid tumors. The Mount Sinai team reports that manipulation of metabolic activity around lysosomes, the storage and recycling centers within cells, can increase by more than 90-fold the potency of blood-forming stem cells in bone marrow transplantation.…

Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise. NEW YORK, NY, CAMBRIDGE, MA, ROTTERDAM, NL, and SUZHOU, CN - Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology. The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies could be used therapeutically for people who…